2. Academic Validation
  3. Enhancement of cancer immunotherapy using CRT valgus tumor cell membranes coated bacterial whole peptidoglycan combined with radiotherapy

Enhancement of cancer immunotherapy using CRT valgus tumor cell membranes coated bacterial whole peptidoglycan combined with radiotherapy

  • Int J Pharm. 2023 Sep 22;123430. doi: 10.1016/j.ijpharm.2023.123430.
Xinhong Li 1,  Yiting Chen 1,  Rui Wang 1,  Enhao Lu 1,  Kuankuan Luo 1,  Xianyi Sha 2
Affiliations

Affiliations

  • 1 Key Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
  • 2 Key Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China; The Institutes of Integrative Medicine of Fudan University, Shanghai, China. Electronic address: [email protected].
PMID: 37742823 DOI: 10.1016/j.ijpharm.2023.123430
Abstract

Immunotherapy has achieved some success in preclinical and clinical studies, but the immunosuppressive tumor microenvironment (TME) leads to a low response rate of this therapy. In this paper, we describe a calreticulin (CRT) valgus CT-26 tumor cell membranes-coated Bacterial whole peptidoglycan (WPG) from P. aeruginosa (CPW/SR) with a high rate of the STING agonist loading. In the construct, WPG from P. aeruginosa (P.WPG) was used as a carrier with the immunoadjuvant function while synergistically promoting the maturation of dendritic cells (DCs) through the delivery of the STING agonist SR-717. CRT valgus tumor cell membranes were identified and internalized by DCs via CRT on the surface. In addition, this construct was able to reverse the immunosuppressive TME in vivo and achieve synergies with radiotherapy by creating a personalized tumor vaccine, therefore achieving more resultful antitumor efficacy. In conclusion, CPW/SR constructed in this paper provides a new approach for achieving efficient Cancer Immunotherapy and combination therapy.

Keywords

bacteria-derived immunoadjuvant; colon cancer; combination therapy; immunotherapy; whole peptidoglycan.

Figures
Products